Skip to content

Lifeward Ltd.'s (LFWD) Earnings Conference Transcript for Q2 2025

Lifeward Ltd. (NASDAQ: LFWD) Holding Its Q2 2025 Earnings Meeting on August 14, 2025 at 8:30 AM ET

Lifeward Ltd.'s Second Quarter Earnings Call Transcript for 2025
Lifeward Ltd.'s Second Quarter Earnings Call Transcript for 2025

Lifeward Ltd.'s (LFWD) Earnings Conference Transcript for Q2 2025

Lifeward Ltd. (NASDAQ: LFWD), a leading company in the healthcare technology sector, held its Q2 2025 Earnings Conference Call on August 14, 2025, at 8:30 AM ET. The press release and webcast of the conference call can be accessed through the Investor Relations section of the Lifeward website at golifeward.com.

The call was led by Almog Adar, the newly appointed Chief Financial Officer of Lifeward, and William Mark Grant, President, CEO, and Director of the company.

In recent months, Lifeward has been experiencing a challenging financial and stock performance period. Analysts have downgraded revenue forecasts for 2025 to $25 million, a modest 2.7% increase from past 12 months, down from previous $28 million estimates. Loss per share is expected to worsen 36% to $1.23 per share. The consensus price target dropped by 7.7% to $8.00, indicating weaker profit expectations and valuation concerns.

These challenges were reflected in the Q2 2025 Earnings Results, where Lifeward reported a quarterly loss of $0.58 per share, missing estimates by a wide margin (expected loss $0.25 per share). Revenues were $5.72 million, falling short of analyst estimates by 11.53% and down from $6.71 million year-over-year.

Despite these financial pressures, Lifeward announced record placement of ReWalk exoskeleton systems for Medicare beneficiaries and ongoing growth in its U.S. sales pipeline. The company also appointed Almog Adar as new CFO in August 2025, possibly to strengthen its executive team in tough market conditions.

However, recent technical signals are bearish across short, mid, and long terms, with multiple negative momentum and oscillator indicators implying downward price pressure continues. Shares have declined approximately 64.5% year-to-date, dropping from $1.73 at the start of 2025 to about $0.615 as of late August.

The statements made on the conference call may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Lifeward specifically disclaims any intent or obligation to update these forward-looking statements.

Participants in the conference call included Benjamin Charles Haynor of Lake Street Capital Markets, LLC, Research Division, Swayampakula Ramakanth of H.C. Wainwright & Co, LLC, Research Division, and I-Eh Jen of Laidlaw & Company (UK) Ltd., Research Division.

Investors should monitor upcoming earnings calls and management commentary for potential shifts. Despite the near-term challenges, Lifeward's operational growth in product deployment and leadership changes offer some positive signs for the future.

Read also:

Latest